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ABSTRACT 
Objective: Epilepsy is a common neurodegenerative disorder characterized by spontaneous and repeated attacks of convulsions. It requires immediate 
pharmacotherapy to prevent its progression to status epilepticus. However, most of the anticonvulsant drugs are poorly water-soluble and demonstrate 
the delayed onset of action. Thus there is a need to improve its solubility for the better pharmaceutical profile. The objective of the present investigation 
was to enhance the solubility of lamotrigine incorporating soya lecithin as a phospholipid carrier by solid dispersion technique  
Methods: Solid dispersions of lamotrigine were prepared with soya lecithin by the solvent method. The effect of concentration of phospholipid and 
solvents on aqueous solubility and dissolution profile of lamotrigine was analyzed.  
Results: Ethanol increased lamotrigine solubility with soya lecithin in ratio 5:1. X-ray diffraction and scanning electron micrograph indicated a 
smaller crystallite size of lamotrigine with fairly uniform size distribution in the lamotrigine-soya lecithin solid dispersion. The resultant solid 
dispersion also significantly delayed the onset of clonic convulsion (875.8 s) as compared to control (85.5 s) and offered complete protection 
(100%) against the pentylenetetrazole induced seizures in the rat as compared to control (33.33%). Also, solid dispersion with maximum drug 
content (77.68%) and dissolution rate (91.40%) was formulated as an orodispersible tablet and characterized for its pharmaceutical properties.  
Conclusion: It can be concluded that the solid dispersion of lamotrigine incorporated with soya lecithin demonstrated enhanced solubility and 
dissolution rate may have potential clinical application. 
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INTRODUCTION 
Epilepsy is a very common neurodegenerative disorder characterized by 
repeated episodes of epileptic attacks. It required immediate medical 
help to prevent its progression to status epilepticus [1]. Although 
pharmacological treatment has been more pronounced due to the 
availability of new generation anticonvulsant drugs, some of them are 
poorly water-soluble and show delayed onset of action following their 
oral administration [2]. Low aqueous solubility is the major problem 
encountered with the formulation development of such drugs [3]. If the 
rate of dissolution of the drug is significantly slower than the rate of 
absorption, the dissolution of the drug becomes the rate-limiting step in 
the absorption process. Different formulation approaches have been 
used to improve the oral absorption of drugs with low water solubility 
by increasing the dissolution rate and solubility [4, 5]. 
Lamotrigine is a second-generation antiepileptic drug that shows a 
broad spectrum of actions against partial, generalized tonic-clonic 
seizures and Lennox-Gastaut syndrome either alone or as adjunctive 
therapy [6, 7]. Comparatively, lamotrigine shows relatively few side 
effects and does not require blood monitoring in monotherapy [8, 9]. 
However, peak plasma concentration reaches after 1.4 h its oral 
administration. This delay in the onset of action in spite of good 
bioavailability is due to its low aqueous solubility (0.17 g/l) [2, 8]. Hence 
it is required to improve the solubility and dissolution of lamotrigine. 
Enhancement of the solubility of poorly water drugs is a difficult 
task. Several methods have been used for solubility enhancement 
such as salt formation [10], complexation [11], solid dispersion [12], 
microcrystals [13], microemulsion [14] etc. One successful approach 
to enhance the solubility is solid dispersions using an appropriate 
carrier. The dissolution rates may be improved by dispersing drugs 
in polymeric carriers by fusion and solvent evaporation methods [3]. 
Though various solid dispersion techniques are available, the 
solvent method is advantageous as it requires low temperature for 
the evaporation of organic solvents that prevents the decomposition 
of drugs and carriers [15]. 
The preparation of solid dispersion using soluble carriers increases the 
solubility and dissolution rate of the drug, as it is exposed to the 
dissolution medium in the very fine particulate form [8, 16]. Hydrophilic 
polymers have been used to enhance the solubility and dissolution rate 
of lamotrigine. Some of the investigators have prepared and evaluated 
the formulations of solid dispersion of lamotrigine using hydrophilic 
polymers [8, 17]. However, it requires a great amount of the carrier for 
the preparation of solid dispersion. Thus it would be useful to use a 
minimum quantity of carriers such as phospholipids as solubility 
enhancers for the preparation of solid dispersion. Phospholipids are 
required in much lower concentration for increasing the dissolution rate 
of poorly water-soluble drugs. These forms spherical bilayer structures 
(liposomes) when it is dispersed in aqueous media into which the drug is 
entrapped or sequestered [18-20] and released rapidly into the 
dissolution medium. Besides the assimilation of drugs with lipids or 
lipid-like compounds promotes the oral absorption of the drug by 
intrinsic lipid pathway [21]. 
Soya lecithin, the phospholipid is a multi-functional surface-active 
agent having various applications. Phospholipids due to their 
amphiphilic property have the solubilizing potential for poorly 
water-soluble drugs [22, 23] can be used as a carrier for the 
preparation of solid dispersion. With this background, the present 
investigation was carried out to enhance the solubility and 
dissolution of lamotrigine incorporating soya lecithin as a 
phospholipid carrier by solid dispersion technique. Also to 
determine the anticonvulsant activity of prepared formulation in 
rats and to develop an orally disintegrating tablet containing solid 
dispersion to achieve fast release of drug from the dosage form. 
MATERIALS AND METHODS 
Materials 
Lamotrigine was obtained as a gift sample from Glenmark, Mumbai, 
soya lecithin was purchased from Himedia Lab. Mumbai, DMSO, and 
methanol were procured from Merck chemicals, Mumbai. Ethanol 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 12, Issue 1, 2020 
Taksande et al. 
Int J App Pharm, Vol 12, Issue 1, 2020, 115-122 
116 
was procured from Changshu Hongsheng Fine Chemical Co. Ltd 
Jiangsu Province. Chloroform was purchased from Loba Chemie 
Mumbai, croscarmellose sodium from Akhil Healthcare Mumbai and 
cross povidone was obtained from Amnem Mumbai, sodium starch 
glycolate was purchased from Sigma Aldrich, Mumbai. All the 
chemicals used in experiments were of analytical grade. 
Preparation of phospholipid solid dispersions and physical 
mixture 
Solid dispersions of lamotrigine and phospholipids were prepared 
by the solvent method [24, 25] using chloroform, DMSO, and ethanol 
as solvent. Weighed amounts of phospholipid and lamotrigine (ratio 
of 1:1, 1:3, 1:5 and 1:10) were added to the solvent and dissolved 
with gentle stirring further sonicated for 30 min after complete 
dissolution solvent was removed at room temperature or up to 60 °C 
temperature if required. Further drying was accomplished in a 
vacuum desiccator overnight. Physical mixtures were prepared by 
gently triturating appropriate quantities of lamotrigine and 
phospholipid using a mortar and pestle. Solid dispersions and 
physical mixtures were passed through an 80-mesh sieve to 
obtained uniform size powder for further studies. The formulation 
composition for solid dispersion is depicted in table 1. 
 
Table 1: Composition of lamotrigine solid dispersion 
Ingredients S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 
PLP: LTG 1:1 1:3 1:5 1:10 1:1 1:3 1:5 1:10 1:1 1:3 1:5 1:10 
DMSO+Ethanol (ml) (2:1) 10 10 10 10 - - - - - - - - 
Ethanol ml) - - - - 10 10 10 10 - - - - 
Chloroform+ Ethanol (ml) (2:1) - - - - - - - - 10 10 10 10 
 
Saturation solubility 
Saturation solubility was performed, adding an excess of the amount 
of sample in 20 ml distilled water in a screw-capped flask and 
shaken in a rotary flask shaker (20 rpm) at room temperature 
(37±0.5 °C) for 48 h. Once equilibrium was achieved appropriate 
aliquots were withdrawn and filtered through Whatman filter paper 
no. 45. The filtrate was analyzed for drug spectrophotometrically at 
307 nm [26]. 
Drug content 
Drug content was determined by dissolving solid dispersion or 
physical mixture equivalent to 10 mg of drug in 10 ml methanol 
following ultra-sonication for 20 min. The volume was adjusted to 
100 ml with a 6.8 pH buffer. The solution was filtered through 
Whatman filter paper no. 45, further suitably diluted with 6.8 pH 
buffer and the absorbance was measured at 307 nm using a double-
beam UV spectrophotometer [27]. 
Dissolution studies 
The dissolution studies were carried out using the TAB dissolution 
test apparatus (Cambell DRS Company). The dissolution flasks were 
immersed in the water bath equipped with an external temperature 
control unit. 10 mg of the sample was dispersed on the surface of the 
dissolution medium at the beginning of the study. A USP standard 
paddle continuously stirred the dissolution medium (900 ml of 6.8 
pH buffer) at 100 rpm at 37±0.5 °C. A sink condition was maintained 
in the dissolution medium. Samples were taken at pre-determined 
intervals and the concentration of lamotrigine present in the 
dissolution medium was determined using a double-beam UV 
spectrophotometer at 307 nm [25]. 
Characterization of lamotrigine phospholipid solid dispersions 
Differential scanning calorimeter (DSC) 
The DSC analysis was performed using Mettler Toledo DSC822e 
using aluminum crucibles with about 6.5-10 mg of samples, under 
dynamic N2 atmosphere (10 ml min−1) and heating rate of 20 °C 
min−1 under a temperature range from 25 °C to 350 °C.  
Powder X-ray diffraction studies (PXRD) 
X-ray diffraction study was performed to determine the crystallinity 
of the prepared solid dispersion using Bruker X-ray diffractometer 
AXS D8 Advance using a Cu radiation (1.5406 Å) at a voltage 2.2 kV, 
and Detector-Si(Li)PSD. Diffractogram was scanned in the range 
from 3 °C to 80 °C (2θ) with a resolution of 0.02 °C and scanning 
speed of 2.0 °C min−1
Fourier-transform infrared spectroscopy (FTIR) spectrum was 
recorded on Thermo Nicolet, Avatar 370 using the potassium 
bromide pellet method. About 2 mg of the sample was mixed with 
potassium bromide, and the mixture was compressed at a pressure 
of 5 tons for 5 min in a hydraulic press to form the pellets. The 
sample was scanned at 4 cm
. 
Fourier-transform infrared spectroscopy  
-1
For the preparation of oral dispersible tablet using solid dispersion 
formulation with maximum drug content and better dissolution 
profile was selected. The formulation composition of lamotrigine 
orodispersible tablets is depicted in table 2. Tablets were prepared 
by the direct compression method by taking solid dispersion 
equivalent to 25 mg of lamotrigine. Microcrystalline cellulose (MCC) 
and mannitol were used as directly compressible agents. Sodium 
starch glycolate (SSG), crospovidone (CPD), croscarmellose sodium 
(CCS) were used as super disintegrant agents in different batches. 
Aspartame was added as the sweetening agent. Talc and magnesium 
stearate were added as lubricant and glidant and compressed as a 
tablet using flat-faced punches. The hardness of the tablets was kept 
constant and was measured with a hardness tester. Tablet blend and 
tablets were evaluated for various pre-compression and post-
compression parameters [17]. 
 resolution. 
Scanning electron microscopy (SEM) 
A JSM-6390LV field emission scanning electron microscope (JEOL, 
Peabody, MA) was used to determine the particle shape and size of 
lamotrigine and solid dispersion. Photomicrograph was taken at 
1500x to 3500x magnification. 
Pharmacodynamic study 
The study was carried out to investigate the anticonvulsant effect 
of an optimized batch of solid dispersion in PTZ induced seizures 
in rats through oral administration. It is commonly used in 
preclinical paradigms for predicting the anti-convulsant activity of 
lamotrigine after their acute administration. Adult male Sprague 
Dawley rats (National Institute of Nutrition; Hyderabad, India) 
weighing 200–280 g were housed in standard laboratory 
conditions of temperature (23±1 °C) and relative humidity 
(55±5%), with free access to food (NIN, Hyderabad, India) and 
water. Animals were divided into different groups (n=4), fasted 
overnight before the experiments and transferred to the 
laboratory at least 1 h before the beginning of the experiment. The 
experiments were performed during the light cycle in between 
9.00 to 13.00 h. All the experimental protocols were approved by 
the Institutional Animal Ethics Committee (853/IAEC/2018-
19/25). Oral doses of solid dispersion (equivalent to lamotrigine: 
5 mg/kg, 10 mg/kg) and pure drug in saline were administered 
using a polyethylene tube. The tube was inserted about 5-6 mm 
deep for the proper delivery of drugs orally. 1 h following drug 
administration, animals were subcutaneously injected with PTZ 
(60 mg/kg) and the onset of clonic-tonic convulsions and 
percentage protection in each group were recorded.  
Development of orodispersible tablet 
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Table 2: Composition of lamotrigine orodispersible tablets 
Ingredients (mg) F1 F2 F3 F4 F5 F6 
SD LTG  26.05 26.05 26.05 26.05 26.05 26.05 
SSG 6 8 - - - - 
CCS - - 6 8 - - 
CPD - - - - 6 8 
Mannitol 49.15 47.45 49.15 47.45 49.15 47.45 
MCC 8.5 8.5 8.5 8.5 8.5 8.5 
Aspartame 3 3 3 3 3 3 
Talc 3 3 3 3 3 3 
Aerosil 2 2 2 2 2 2 
Mg stearate 2 2 2 2 2 2 
Total Weight  100 100 100 100 100 100 
 
Statistical analysis 
All the results are reported as mean±standard deviation (SD) or 
mean±standard error mean (SEM). Statistical comparisons were 
performed by one-way analysis of variance followed by Bonferroni’s 
multiple comparison test. Differences between formulations were 
considered to be statistically significant at P<0.05 in all cases. 
RESULTS AND DISCUSSION 
Preparation and characterization of lamotrigine solid 
dispersion 
Solid dispersion of lamotrigine-soya lecithin was prepared by the 
solvent method. Preformulation studies were performed for 
lamotrigine solubility in ethanol, chloroform, DMSO, ethanol-
chloroform and DMSO-ethanol to select the solvent system for the 
preparation of solid dispersion. Based on the results solid dispersions 
were prepared by using DMSO-ethanol (2:1), chloroform-ethanol (2:1) 
and ethanol as solvents. The aqueous solubility of pure lamotrigine 
was found to be 0.1515 mg/ml. Solid dispersions were prepared by 
using the various ratio of lamotrigine and soya lecithin using different 
solvent were analyzed for aqueous solubility. Results revealed an 
increase in solubility was for the batch S7 prepared by using ethanol 
as a solvent in comparison to other solvents. Solid dispersion prepared 
with DMSO and ethanol showed an increase in solubility of lamotrigine 
as compared to that of the pure drug, but the preparation was more 
viscous and difficult to dry. Batches prepared with ethanol and 
chloroform as solvent showed an increase in aqueous solubility, but 
results were more enhanced for the solid dispersions prepared with 
ethanol as solvent. Batch S7 consisting of soya lecithin and lamotrigine 
in ratio 1:5 showed a significant increase in aqueous solubility of 
lamotrigine i.e. 3.1814 mg/ml as compared to its lower ratios(1:1 and 
1:3). However, a further increase in ratio showed a decreased 
solubility. A physical mixture of lamotrigine with soya lecithin showed 
an increase in aqueous solubility than pure drug, but it was very less 
as compared to aqueous solubility of various solid dispersions. Table 3 
depicts the results for the effect of solvents and the ratio of 
phospholipid and lamotrigine on the saturation solubility of 
lamotrigine. 
The drug content of the formulation was ranging from 41.39 % to 
77.68 %, indicating maximum entrapment of drug in the 
formulation. The maximum amount of drug content 77.68±1.35% 
was obtained for solid dispersion with a 1:5 ratio of soya lecithin 
and lamotrigine using ethanol as solvent. The percentage of drug 
content proportionally increased with the drug concentration. 
  
Table 3: Saturation solubility of lamotrigine, solid dispersions and physical mixture 
Formulation code Media Solubility (mg/ml) Drug content*(% w/w) 
LTG 6.8 Buffer 0.4882 - 
LTG Ethanol 1.8232 - 
LTG water 0.1515 - 
S1 water 1.6501 41.39±0.77 
S2 water 1.7528 49.84±1.68 
S3 water 1.8804 61.69±1.75 
S4 water 2.2552 69.37±0.57 
S5 water 0.1942 39.83±1.95 
S6 water 2.9986 57.46±5.90 
S7 water 3.1814 77.68±1.35 
S8 water 3.0400 72.55±1.27 
S9 water 1.9821 40.4±1.94 
S10 water 2.0447 50.84±0.86 
S11 water 2.2356 70.32±0.64 
S12 water 2.3252 68.56±1.16 
PM water 0.1787 62.7±1.06 
Results are shown as mean±SD (* n=3) 
 
Dissolution studies 
The lamotrigine-soya lecithin solid dispersions prepared from 
ethanol exhibited greater dissolution as particles formed were fine, 
non-waxy and discrete. Fig. 1 shows the effect of different ratios of 
lamotrigine to soya lecithin on the dissolution of lamotrigine. 
Increasing the soya lecithin content in this system from 5:1 to 1:1 
showed a significant increase of 96.68±0.41% in the extent of 
dissolution at 75 min; also the initial rate of dissolution at 5 min was 
increased. However, the results were slightly decreased for the 
system containing lamotrigine and soya lecithin ratio 10:1. There 
were no significant differences in dissolution between 5:1 and 10:1 
ratios of lamotrigine to soya lecithin. This illustrates that a small 
amount of the carrier phospholipid was adequate for a significant 
increase in the rate and extent of dissolution. An increase in 
dissolution rate was observed for the solid dispersions as compared 
to physical mixture and lamotrigine. This might be because of the 
decrease in particle size of the crystallites, resulting in greater 
wetting and increase in surface area of particles or because the 
crystallites are coated with the phospholipid or both. When placed 
into an aqueous medium, phospholipids rapidly form liposomal 
structures on dispersion resulting in an effective increase in the 
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saturation concentration of drugs in the diffusion layer during the 
dissolution process through the release of substantially entrapped 
finely dispersed drug from the lipid bilayer or the aqueous 
compartments. This may be another reason for the increased 




Fig. 1: Dissolution profile of a) DMSO and ethanol (2:1) treated solid dispersions of lamotrigine with a phospholipid, b) ethanol-treated 
solid dispersions of lamotrigine with phospholipid and c) chloroform and ethanol (2:1) treated solid dispersions of lamotrigine with 
phospholipid in 6.8 pH buffer 
 
Characterization of lamotrigine phospholipid solid dispersions 
Differential scanning calorimeter (DSC) 
DSC thermogram of lamotrigine, lamotrigine-soya lecithin physical 
mixture and solid dispersion of lamotrigine-soya lecithin prepared 
by using ethanol are depicted in fig. 2. The studies revealed the 
formation of lamotrigine solid dispersion with and broaden 
endothermic peak at 206.69 °C by the solvent method. DSC 
thermograph of pure lamotrigine exhibited a sharp endothermic 
peak at 217.48 °C suggests the melting temperature of lamotrigine 
which has shifted backward and becoming much broader, suggests 
the formation of crystals of solid dispersion with soya lecithin. 
  
 
Fig. 2: DSC spectral analysis of a) lamotrigine, b) lamotrigine-soya lecithin physical mixture and c) Solid dispersion of lamotrigine-soya 
lecithin using ethanol 
 
X-ray diffraction studies (XRD) 
XRD analysis of lamotrigine, lamotrigine-soya lecithin physical 
mixture and solid dispersion of lamotrigine-soya lecithin prepared 
by using ethanol are depicted in fig. 3. The X-ray diffractogram of 
lamotrigine shows a sharp and intense peak indicating the 
crystalline nature of the drug in pure form. The X-ray diffractogram 
of the physical mixture and solid dispersion were obtained to 
determine if there is a loss or modification of the pure drug’s crystal 
structure after it is formed into a solid phospholipid dispersion, and 
to determine if any new crystalline phases may have formed. Fig. 3 
indicates that there is virtually no difference in crystallinity between 
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prepared solid dispersion and pure lamotrigine proposed that 
enhanced dissolution might be due to the increased surface area of 
the drug crystallites after the formation of the solid dispersions and 
not due to a change from a crystalline to an amorphous state [25]. 
 
 




Results of FTIR spectral analysis of lamotrigine, soya lecithin, physical 
mixture of lamotrigine-soya lecithin and solid dispersion of lamotrigine-
soya lecithin are depicted in fig. 4. FTIR spectra of lamotrigine showed 
characteristic absorbance at 3448 cm-1 specifying NH stretching of an 
amino group (Aromatic), 3209 cm-1 shows aromaticity (aromatic CH 
stretching), 1620 cm-1, 1486 cm-1 indicates C=C ring stretching and 962 
cm-1
Thus, based on DSC, XRD, and FTIR analysis, the formation of 
crystallites of solid dispersion was affirmed.  shows C-Cl stretching of halides. In FTIR spectra of physical mixture 
characteristics peak of both lamotrigine and soya lecithin were observed. 
It suggests no significant interaction between drug and excipient. 
However, the characteristic absorbance peaks of lamotrigine were found 
to be shifted to lower values and decreased in intensity also, suggesting 
the formation of solid dispersion of lamotrigine with soya lecithin by 
using ethanol as solvent.  
 
 
Fig. 4: FTIR spectral analysis of a) lamotrigine, b) soya lecithin, c) lamotrigine soya lecithin physical mixture and d) Solid dispersion of 
lamotrigine using ethanol 
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Scanning electron microscopy (SEM) 
Fig. 5 shows SEM images of the lamotrigine and solid dispersion 
of lamotrigine-soya lecithin. As observed from the fig. 5 particles 
of lamotrigine–soya lecithin solid dispersion showed the regular 
shape and smooth surface and significant reduction of the 
lamotrigine crystallite size as compared to pure lamotrigine. 
This allows faster solvating of the drug and the faster breakup of 
the solid dispersions. This could be because the crystallites are 
less than a micron in size. This may be the reason for the 
increased dissolution of lamotrigine from the lamotrigine-soya 
lecithin solid dispersion. 
 
 
Fig. 5: SEM image of a) Lamotrigine and b) Solid dispersion of lamotrigine using ethanol 
 
Pharmacodynamic study 
As shown in fig. 6, administration of PTZ to vehicle-treated rat 
produced clonic convulsions in all animals, and the onset of such 
convulsions was 85.5±14.36 s. Oral administration of solid 
dispersion of lamotrigine (10 mg/kg) significantly delayed the onset 
of clonic-tonic seizures in PTZ injected animals up to 875.75 s as 
compared to administration of lamotrigine powder (634 s). It also 
offered 100% protection against the mortality induced by PTZ which 
was 66.66% with lamotrigine powder. Similarly, administration of 
solid dispersion of lamotrigine in dose 5 mg/kg too delayed the 
onset of clonic-tonic seizures in PTZ injected animals up to 691.25 s 
and provided 100% protection against mortality induced by PTZ. 
The results indicate the greater anticonvulsant effect of lamotrigine-
soya lecithin solid dispersion in PTZ-induced seizures as compared 
to pure lamotrigine. The results of the study are also supported by 
our earlier observations demonstrating the anticonvulsant effect of 
lamotrigine in PTZ induced clonic tonic seizures [28, 29]. 
 
 
Fig. 6: Effect of lamotrigine solid dispersion on the mean onset time of convulsions against pentylenetetrazole-induced seizures. 
***P<0.001 as compared to control group; #P<0.001 as compared to the control group. Data are represented as the mean onset time of 
convulsions±SEM. Statistical analysis by ANOVA followed by Bonferroni's multiple comparison test (n = 4) 
 
Characterization of lamotrigine orodispersible tablets 
Precompression studies 
Solid dispersion of batch S7 consisting of 1:5 ratio of soya lecithin-
lamotrigine was obtained as discrete, uniform and non-greasy 
particles showed maximum drug content, better dissolution profile 
as compared to other batches and significant anticonvulsant activity 
so it was selected for the formulation of orodispersible tablets. The 
tablet blend was prepared by using various super disintegrants such 
as SSG, CCS, and CPD. The powder blends were evaluated for various 
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pre-compression parameters of powder blend and results are 
depicted in table 4. The bulk density found to be in range 
0.523±0.003 to 0.558±0.002 g/cm2
 
, which was within acceptable 
limits. The angle of repose of all the formulations was found to be 
less than 25 ° indicated excellent flowability of the powder blend. 
Another important parameter to determine powder compressibility 
and flowability is the Hausner’s ratio. A ratio greater than 1.5 
indicates cohesive and poor flow property of powder blend. Results 
revealed the values less than 1.5 indicates good flow and 
compression property of the powder blends. Results of Carr’s index 
also indicate acceptable flow property and compression behavior 
powder blend to be compacted as tablets. 
Table 4: The Pre-compression evaluation parameters of the powder blend 
Formulations Bulk density (g/ml) Tapped density (g/ml) Carr’s index (%) Hausner’s ratio Angle of repose (θ) 
F1 0.545±0.001 0.761±0.003 28.38±1.23 1.396±0.025 19.28±0.65 
F2 0.558±0.003 0.727±0.004 26.77±0.98 1.302±0.031 19.89±0.88 
F3 0.551±0.004 0.738±0.002 25.33±0.56 1.339±0.011 20.12±0.76 
F4 0.523±0.002 0.691±0.003 21.10±0.57 1.321±0.014 20.33±0.65 
F5 0.564±0.01 0.716±0.006 23.22±0.87 1.269±0.023 19.66±0.63 
F6 0.534±0.005 0.696±0.004 22.27±1.05 1.303±0.046 19.35±1.03 
Results are shown as mean±SD (n=3) 
 
Post compression studies 
Orodispersible tablets were evaluated for post-compression 
properties and results are depicted in table 5. For all formulations, 
results of weight variation were found to be within limit 100±1.448. 
The hardness test indicated a good mechanical strength of 3.33±0.87 
kg/cm2
 
. The friability was obtained to be less than 1% which 
indicates that all the batches have good mechanical resistance. The 
tablets were evaluated for the in vitro disintegration time, results 
revealed less disintegration time 22.59 s for the tablets consisting of 
CCS. The disintegration time was more with SSG which might be due 
to the formation of a viscous gel layer which leads to a thick barrier 
to further penetration of the disintegration medium and hindered 
the disintegration of tablet content. Thus the tablet disintegration is 
retarded to some extent with the tablet containing SSG when 
compared with the disintegration time of the tablet containing CCS. 
The release profile for a formulation containing various super 
disintegrant and magnesium stearate as a lubricant is depicted in fig. 
7. The drug content of the formulation was ranging from 82.31% to 
95.27 % indicating maximum entrapment of drug in the formulation. 
F1 formulation gives 89.08 % at 15 min and F3, F4 also shows 
significant release 96.34 %, 100.06% respectively. These results 
revealed that maximum drug release was observed when 
lamotrigine was combined with soya lecithin in a 1:5 ratio for solid 
dispersion prepared by the solvent method using ethanol as solvent 
and CCS as a super disintegrating agent. 
Table 5: The post-compression evaluation parameters of formulations 
Code Weight variation$ Hardness* (kg/cm(mg) 2 Friability) # Thickness* (mm) (%) Disintegration* (s) Drug content* (%) 
F1 100±1.0 3.50±0.47 0.60±0.05 3.11±0.14 26.11±0.41 82.31±0.77 
F2 100±1.12 3.40±0.18 0.70±0.04 3.09±0.23 24.45±0.52 91.04±0.68 
F3 100±1.43 3.30±0.43 0.60±0.03 3.18±0.19 23.33±0.63 89.39±1.75 
F4 100±1.44 3.33±0.87 0.50±0.02 3.13±0.17 22.59±0.55 95.27±0.57 
F5 100±1.83 3.29±0.50 0.90±0.01 3.12±0.05 25.15±0.47 86.02±1.95 
F6 100±1.13 3.5±0.83 0.80±0.03 3.16±0.11 27.32±0.12 90.97±0.90 
Results are shown as mean±SD (* n=3, $ n= 20, # n=6) 
 
 
Fig. 7: Dissolution profile of various formulation of lamotrigine 
solid dispersion prepared by using ethanol 
 
CONCLUSION 
In this study, we have prepared the orally disintegrating tablet consisting 
of solid dispersion of lamotrigine with soya lecithin as phospholipid. 
Solid dispersion of soya lecithin-lamotrigine using ethanol as a solvent 
showed a significant increase in solubility over and above the increase in 
rate and extent of dissolution, which may increase the bioavailability of 
lamotrigine. The improved dissolution behavior of drug–phospholipid 
solid dispersions is expected due to the significant increase in the drug's 
total surface area during the dissolution process. Solid dispersion of 
lamotrigine with soya lecithin also showed significant antiepileptic 
activity as compared to pure lamotrigine. Also, optimized solid 
dispersion on oral administration delayed the onset of convulsions and 
offered complete protection against the PTZ induced seizures compared 
to pure lamotrigine. ODT consisting of solid dispersion exhibited fast and 
greater release of lamotrigine. Thus the formulation of lamotrigine solid 
dispersion as ODT offers promising advantages over conventional 
dosage with its immediate onset of action. 
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